NVAX

#2252
Novavax Inc
8.18 USD
+0.86%
版块: 医疗保健
基础: USD
利润货币: USD
日范围
8.14
8.19
年范围
5.80
11.97
日变化
+0.86%
每月变动
-21.12%
6个月变化
-8.50%
年变化
+28.01%
前一天收盘价
8.11
开盘价
8.17
买价
卖价
最低价
8.14
High
8.19
交易量
461
展开完整图表

Financials

概览 声明 统计 股息
每季度 年度
  • Market Capitalization 1.33 B
  • Employee 749
  • Founded 1987
  • CEO John C. Jacobs
  • Website www.novavax.com
  • Headquarter Delaware, United States
  • FIGI BBG000NVSBL7
  • Industry Technology
总收入
净利润
每股基本收益（基本 EPS）
总债务
自由现金流
现金及现金等价物
市盈率
2.6
市销率
1.04

Novavax Inc

Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria. Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine.

新闻